LIVE NOW: FDA Holds Public Meeting on Rare Disease Drug Development Framework

The U.S. Food and Drug Administration, in partnership with the Reagan-Udall Foundation for the FDA, holds a hybrid public meeting at 1 p.m. ET on Oct. 28 to gather input on its Rare Disease Framework Initiative. The meeting focuses on improving regulatory approaches to rare disease drug development, including evidence requirements, regulatory consistency, patient engagement, and manufacturing considerations for therapies targeting small patient populations.

We had a problem loading this article. Please enable javascript or use a different browser. If the issue persists, please visit our help center.